一、董事会会议召开情况 证券代码：000423 证券简称：东阿阿胶 公告编号：2025-45 东阿阿胶股份有限公司 第十一届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 1．东阿阿胶股份有限公司（以下简称"公司"）第十一届董事会第十一次 会议，于 2025 年 8 月 17 日以邮件方式发出会议通知。 2．本次董事会会议，于 2025 年 8 月 20 日以现场会议方式，在公司会议室 召开。 3．会议应出席会议董事 9 人，实际出席会议董事 9 人。 4．本次董事会会议由董事长程杰先生主持，公司监事、高管列席会议。 5．本次董事会会议的召开，符合有关法律、行政法规、部门规章、规范性 文件和公司章程等规定。 二、董事会会议审议情况 经与会董事认真讨论，本次会议审议并通过了以下议案： 1.《关于 2025 年半年度报告及摘要的议案》 本议案提交董事会前，已经公司第十一届董事会审计委员会审议通过。 经审议，董事会认为公司《2025 年半年度报告全文及其摘要》的编制，符 合法律法规、中国证监会和深圳证券交易所的相关规定。报告内容真实、准确 ...

东阿阿胶股份有限公司 2025 年半年度报告 东阿阿胶股份有限公司 2025 年半年度报告全文 1 【披露时间】 东阿阿胶股份有限公司 2025 年半年度报告全文 2 东阿阿胶股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人孙金妮、主管会计工作负责人及会计机构负责人(会计主管人 员)丁红岩声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 公司经本次董事会审议通过的利润分配预案为：以 643,976,824 股为基 数，向全体股东每 10 股派发现金红利 12.69 元（含税），送红股 0 股（含税）， 不以公积金转增股本。 3 | 第一节 | 重要提示、目录和释义 | | 3 | | --- | --- | --- | --- | | 第二节 | 公司简介和主要财务指标 | | 7 | | 第三节 | 管理层讨论与分析 | | 10 | | 第四节 | 公司治理、环境和社 ...

证券代码：000423 证券简称：东阿阿胶 公告编号：2025-48 东阿阿胶股份有限公司 本次利润分配方案实施时，如享有利润分配权的股份总额发生变动，则以实 施分配方案时股权登记日的享有利润分配权的股份总额为基数，按照分配总额不 变的原则对每股分红金额进行调整。 三、现金分红方案的合理性 关于 2025 年中期利润分配方案的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、审议程序 2025 年 5 月 20 日，东阿阿胶股份有限公司（以下简称"公司"）召开 2024 年年度股东大会，审议通过了《关于 2025 年中期分红安排的议案》，授权董事会 制定 2025 年中期利润分配方案。 2025 年 8 月 20 日，公司第十一届董事会第十一次会议，以 9 票同意、0 票 反对、0 票弃权的表决结果，审议通过了《关于 2025 年中期利润分配方案的议 案》。本次利润分配事项已获得股东大会授权，无需提交股东大会审议。现将相 关事宜公告如下： 二、2025 年中期利润分配方案基本情况 本次利润分配方案为 2025 年半年度利润分配，依照《公司法》和《公司章 ...

Core Viewpoint - As of August 20, a total of 119 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more, indicating strong investor interest in these stocks [1] Group 1: Stocks with Significant Net Buying - The stock with the longest consecutive net buying days is Jichuan Pharmaceutical, which has seen net buying for 15 consecutive trading days [1] - Other notable stocks with significant net buying days include Suzhou Bank, ST Guangwu, Te Bao Biological, Jinmoly Co., Ningbo Fuda, Dong'a Ejiao, Xidamen, and China Power [1]

Core Insights - The article highlights the trend of net inflows of main funds into various stocks, with a total of 71 stocks experiencing net inflows for five consecutive days or more as of August 20 [1] Group 1: Stocks with Significant Net Inflows - Suzhou Bank leads with 11 consecutive days of net inflows, followed by Dong-E E-Jiao with 10 days [1] - Fuyao Glass recorded the highest total net inflow amounting to 966 million yuan over six days, while Yunnan Tin Company followed closely with 946 million yuan [1] - Renhe Pharmacy has the highest proportion of net inflow relative to trading volume, with a 22.26% increase in net inflow over five days [1] Group 2: Performance Metrics of Selected Stocks - Fuyao Glass (stock code: 600660) had a net inflow of 966 million yuan, with a cumulative increase of 10.52% over six days [1] - Yunnan Tin Company (stock code: 002428) saw a net inflow of 946 million yuan and a significant cumulative increase of 27.35% [1] - Other notable stocks include Shengyi Technology (688183) with a net inflow of 426 million yuan and a 4.72% increase, and Huahai Pharmaceutical (688120) with a net inflow of 313 million yuan and a 7.76% increase [1]

Core Insights - As of August 19, a total of 138 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stock with the longest streak of net buying is Jichuan Pharmaceutical, which has seen net buying for 14 consecutive trading days [1] - Other notable stocks with significant net buying days include Dingyang Technology, Suzhou Bank, Zhongzhi Holdings, ST Guangwu, Zheshang Bank, Tebao Biological, Yangmei Chemical, and Dong'e Ejiao [1]

Group 1 - The core viewpoint of the article highlights the decline in the production of traditional Chinese medicine (TCM) in China, with a projected decrease in output and significant year-on-year reductions [1][3] - According to data from the National Bureau of Statistics, the production of TCM in China is expected to be 156,000 tons by June 2025, representing a year-on-year decrease of 6.6% [1] - In the first half of 2025, the cumulative production of TCM in China reached 875,000 tons, showing a cumulative decline of 13% [1] Group 2 - The article lists several publicly listed companies in the TCM sector, including Yunnan Baiyao, Tongrentang, and others, indicating the key players in the industry [1] - The report referenced is the "2025-2031 China Traditional Chinese Medicine Industry Development Situation Analysis and Industry Prospect Planning Report" published by Zhiyan Consulting, which provides insights into the future of the TCM industry [1][2]

Industry Overview - The number of registered companies in China's Ejiao industry has shown a growth trend, with over 600 companies registered as of June 2025, and nearly 200 new companies added between 2016 and 2020 [1][3] - The production of Ejiao blocks in China is projected to increase, with an estimated production of 4,379 tons in 2024 [3] Supply Situation - The sales-to-production ratio of Dong'e Ejiao has been declining over the past three years, dropping from 100.9% in 2022 to 97.9% in 2024, indicating increased inventory pressure [5] Demand Scale - The market size of the Ejiao industry in China is expected to reach approximately 29.1 billion yuan in 2024, driven by rising disposable income and increased health awareness among consumers [7] Price Trends - The prices of Ejiao products from major brands like Dong'e Ejiao and Fupai Ejiao have remained stable, with Dong'e Ejiao priced at 2,700 yuan per kilogram and Fupai Ejiao at approximately 1,260 yuan per kilogram [9]

Group 1 - The 18th West China Health Industry Ecological Conference opened in Boao, Hainan, focusing on the theme "Rapid Transformation, Crossing New Cycles," gathering outstanding entrepreneurs, scientists, investors, and experts from various sectors of China's health industry [1] - Dong-E E-Jiao Co., Ltd. (referred to as "Dong-E E-Jiao") participated as a benchmark enterprise, sharing its "1238" strategy, which emphasizes the health supplement industry, embraces new technologies, and explores new models through technological innovation and cultural-industry integration [3] - The launch ceremony of "Qi Heart Gathering Power for a Healthy China - Dong-E E-Jiao & Kangyuan Pharmaceutical Astragalus Essence" took place during the conference, highlighting a collaboration aimed at enhancing the product matrix for energy and blood health [3] Group 2 - The introduction of Dong-E E-Jiao Astragalus Essence is a strategic move to expand business boundaries, responding to diversified and refined health consumption demands, and injecting new vitality into the "National Treasure of Nourishment" brand [5] - Dong-E E-Jiao has established a strategic partnership with Jiuzhoutong to deepen brand collaboration and enhance consumer service experiences through digital marketing innovations [5] - The company aims to continue strengthening technological leadership and developing high-quality products to provide diverse choices for consumers' healthy lifestyles [5]

Group 1 - The core viewpoint of the news is the strong performance of the Chinese traditional medicine sector, highlighted by the rise of the Zhongzheng Traditional Chinese Medicine Index and its constituent stocks following a new policy from the Liaoning Provincial Medical Insurance Bureau [1][2] - The Zhongzheng Traditional Chinese Medicine Index (930641) increased by 1.62%, with notable gains from Tian Shili (600535) up 8.03%, Xin Tian Pharmaceutical (002873) up 7.01%, and Da Ren Tang (600329) up 6.07% [1] - The new policy includes the integration and regulation of three types of medical service pricing, specifically incorporating 39 medical service items, including "traditional Chinese medicine plaster," into the provincial basic medical insurance and work injury insurance fund payment scope, effective from August 20, 2025 [1] Group 2 - Dongwu Securities indicates that the innovative drug industry in China has reached a turning point, with significant advancements in both policy and research and development [2] - The policy framework, including the "Full Chain Support for Innovative Drug Development Implementation Plan," provides support across payment, approval, and financing sectors, facilitating industry growth [2] - As of Q1 2025, the coverage of First-in-Class (FIC) innovative drugs in China reached 40%, with a notable presence of dual-antibody pipelines at the 2025 ASCO conference, indicating global academic recognition [2] Group 3 - As of July 31, 2025, the top ten weighted stocks in the Zhongzheng Traditional Chinese Medicine Index accounted for 54.58% of the index, with key players including Yunnan Baiyao (000538) and Pian Zai Huang (600436) [3]